Pharmacological Effects Of Aniracetam
Racitant-like brain cell metabolizing drugs
Aniracetam, also known as aniracetam, belongs to the racetam class of brain cell metabolizing drugs along with piracetam and nafetilacetam. This class of drugs enhances neuronal intrasynaptic phospholipase activity and increases the formation and transport of ATP in the brain, increases protein and RNA synthesis, promotes the brain's utilization of amino acids, phospholipids, glucose and oxygen, and increases the patient's reactivity, excitability and memory. Aniracetam has stronger effects than piracetam and milder adverse effects.
Pharmacological effects
Aniracetam is a cyclized derivative of γ-aminobutyric acid, which is a brain function improvement drug. It can selectively act on the central nervous system through the blood-brain barrier. It has an activating effect on brain cell metabolism and a protective effect on nerve cells. It can also produce pro-intellectual effects by affecting the glutamate receptor system. It also improves cortical resistance to hypoxia and prevents learning and memory deficits caused by various chemicals, hypercapnia, scopolamine or electroshock. It has no sedative or stimulant effect, and no vasodilator effect. Animal experiments have proved that this product has a good promotion effect on the memory reproduction process of discrimination learning in normal rats, can counteract hypoxia-induced memory loss, and can effectively improve the memory impairment caused by certain reasons.
Indications
Clinically used for the treatment of mild and moderate learning, memory and cognitive dysfunction of vascular dementia and Alzheimer's disease. It is also used for post-stroke memory loss, benign memory impairment in middle-aged and elderly people, and children with delayed brain development.
Pharmacokinetics
The literature reports that the drug is rapidly absorbed after oral administration in rats, with peak blood concentrations in 20-40 minutes. The drug is mainly distributed in the gastrointestinal tract, kidney, liver, brain and blood, and after 24 hours, 77%-85% is excreted in the urine and 4% in the feces. The main metabolites in urine are: N-p-methoxybenzoylaminobutyric acid and 5-hydroxy-2-pyrrolidinone. Human: After oral absorption, the elimination half-life of the original drug in the blood is 20-30 minutes on average, and the blood concentration is difficult to be measured after 2 hours.
Adverse reactions
Adverse reactions are rare, occasionally dry mouth, anorexia, constipation, dizziness, drowsiness, disappear after discontinuation of the drug.
Precautions
(1) The dose administered should be adjusted appropriately in the presence of significant liver function abnormalities.
(2) This product may aggravate the symptoms of Huntington's chorea.
(3)This product is contraindicated in patients who are allergic to it or who cannot tolerate other pyrrolidone-based drugs.
(4)The recommended safe use range of this product is 0.3~1.8g/d.
Chemical properties
Crystallized from ethanol, melting point 12l～122℃. Acute toxicity LD50 rats, mice (mg/kg): about 4500, >5000 orally.
Uses
Aniracetam is a derivative of piracetam, which is a γ-lactone It can pass the blood-brain barrier and act selectively on the central nervous system and brain tissue to improve brain function and memory, and has the function of promoting and enhancing memory. Compared with piracetam, it has the advantages of strong action, fast onset of action and low toxicity. Animal experiments have proved that it has good promotion effect on memory reproduction process of discriminative learning in normal rats, can counteract memory loss caused by hypoxia, and can effectively improve memory impairment caused by certain reasons. It is clinically used for the treatment of senile dementia, memory loss after cerebrovascular disease and memory loss in middle and old age.
